Barr Pharmaceuticals Inc

Barr Pharmaceuticals — Merger or Acquisition (July 2008)

37 slides from Barr Pharmaceuticals's merger presentation, Jul 24, 2008

  1. Slide 1: Final Transcript: Teva and Barr acquisition luncheon

    Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomson StreetEvents Thomso

  2. Slide 2: Compelling Value Creation

    Strong strategic fit Attractive economics Extends global market leadership Exceeds 20/20 strategic target Expands product portfolio and pipeline + Compelling Value Creation

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995 The statements, analyses and other information contained herein relating to the proposed merger and anticipated synergies, savings and financial and operating performance, including estimates

  4. Slide 4: Agenda

    Agenda Introduction Shlomo Yanai - Strategic rationale and business opportunity Bruce Downey - Barr's unique contribution to Teva Bill Marth - Contribution to our U.S. business Gerard Van Odijk - Contribution to our global business Eyal Desheh - Financial aspects of the transaction Phil Frost - Mess

  5. Slide 5: Teva's Acquisition of Barr: Extending Leadership and Accelerating Growth

    Shlomo Yanai President and CEO, Teva Pharmaceutical Industries Teva's Acquisition of Barr Extending Leadership and Accelerating Growth July 21, 2008

  6. Slide 6: Compelling Value Creation

    Compelling Value Creation Enhances U.S. leadership Expands product portfolio and pipeline Augments long-term biologics capabilities Strengthens presence in key global markets Strong strategic fit Attractive economics Accretive in the fourth quarter after closing Exceeds 20/20 target At least $300 mi

  7. Slide 7: Barr Significantly Accelerates Teva's Growth Strategy

    Barr Significantly Accelerates Teva's Growth Strategy From Teva's Investors' Presentation - February 21, 2008 Supports all five pillars Adds new dimensions 2

  8. Slide 8: For Each Strategic Pillar, Barr Extends and Accelerates

    For Each Strategic Pillar, Barr Extends and Accelerates ... Increase Teva's market share in key markets Leadership in generics across U.S. and in key global markets Further separation from the pack Double our product portfolio Biologics: the next growth wave in generics Redefine customer service Inn

  9. Slide 9: Elevating Teva's Market Leadership

    From Teva's Investors' Presentation - February 21, 2008 Barr Significantly Accelerates Teva's Growth Strategy Elevating Teva's market leadership 4

  10. Slide 10: Separating from the Pack: Teva's Lead Will Grow Significantly

    $2.5 B Separating from the Pack: Teva's Lead Will Grow Significantly 2007 Global Peer Group Sales $9.4 B $7.2 B Sandoz $4.2 B Mylan* Ratio- pharm $2.3 B $2.5B Stada $11.9 B 1.6 5 * Proforma and full year for Merck Source: Company filings and websites +

  11. Slide 11: Unparalleled Leadership in the U.S.

    Unparalleled Leadership in the U.S. 0.5 6 Sandoz 0.5 M 0.6 M 0.8 M 1.6 M Mylan Watson Teva Barr 2x Pro forma number of TRxs per day 596.1 M 295.4 M 236.6 M 202.8 M

  12. Slide 12: Expands Global Market Presence

    Expands Global Market Presence Before U.K. Italy Netherlands Spain #1 #1 #1 #7 4.5 Hungary #3 France #4 Belgium #5 Czech Republic #2 Direct sales in more than 60 countries 7

  13. Slide 13: For Each Strategic Pillar, Barr Extends and Accelerates

    For Each Strategic Pillar, Barr Extends and Accelerates ... Increase Teva's market share in key markets Leadership in generics across U.S. and in key global markets Further separation from the pack Double our product portfolio Biologics: the next growth wave in generics Redefine customer service Inn

  14. Slide 14: Portfolio Advantage

    Portfolio Advantage 500+ marketed products 200+ ANDAs ~70 first-to-file Paragraph IV challenges ~$120 billion in branded sales addressed by combined ANDA pipeline ~3,700 product registrations pending in Europe and worldwide 9

  15. Slide 15: For Each Strategic Pillar, Barr Extends and Accelerates

    For Each Strategic Pillar, Barr Extends and Accelerates ... Increase Teva's market share in key markets Leadership in generics across U.S. and in key global markets Further separation from the pack Double our product portfolio Biologics: the next growth wave in generics Redefine customer service Inn

  16. Slide 16: Attractive Economics

    Attractive Economics Cost synergies Revenue upside At least $300 million captured within 3 years of closing Additional cost savings well beyond 2011 Barr's portfolio + Teva's commercial engine Further growth of Women's Health Accretive deal Expected to be accretive in the fourth quarter after closin

  17. Slide 17: Compelling Value Creation

    Strong strategic fit Attractive economics Extends global market leadership Exceeds 20/20 strategic target Expands product portfolio and pipeline + Compelling Value Creation 12

  18. Slide 18: Teva's Acquisition of Barr: Bill Marth, Teva North America

    Teva's Acquisition of Barr Extending Leadership and Accelerating Growth July 21, 2008 Bill Marth President and CEO, Teva North America

  19. Slide 19: Barr Extends and Accelerates Our 2012 Strategy for North America

    Barr Extends and Accelerates Our 2012 Strategy for North America Increase Teva's market share in key markets Double our product portfolio Biotechnology: Next growth wave in generics Redefine customer service Innovative business Expands portfolio and pipeline leadership Widens gap versus next largest

  20. Slide 20: Expands Portfolio and Pipeline Leadership

    Expands Portfolio and Pipeline Leadership 150 331 481 Teva + Barr Sandoz Mylan Watson 2.4x 149 218 Teva + Barr Sandoz Mylan 69 Watson 2.0x U.S. Generic Portfolio Marketed products U.S. Generic Pipeline Pending ANDAs 60 2

  21. Slide 21: Strengthens Our Big-to-Big Value Proposition

    Strengthens Our Big-to-Big Value Proposition Customer mergers since 2006 Our scale improves our service Production capacity can be rapidly "flexed" to meet the largest orders Capacity increases by ~25% 62 billion dosage forms per year Financial flexibility to invest in joint programs that: Increase

  22. Slide 22: Doubles Our Specialty Products

    Doubles Our Specialty Products Leading Brands Teva Barr 2007 U.S. sales ~$400M ~$400M ~$800M 4

  23. Slide 23: Advances Our Efforts in Biogenerics

    Advances Our Efforts in Biogenerics R&D sites GMP production capacity Products in development Number of scientists 5

  24. Slide 24: Key Takeaways

    Extends our portfolio leadership Strengthens our Big-to-Big value proposition Doubles our specialty offerings Advances our efforts in biogenerics Key Takeaways + 6

  25. Slide 25: Teva's Acquisition of Barr: Gerard van Odijk, Teva Europe

    July 21, 2008 Gerard W.M. van Odijk President and CEO, Teva Europe Teva's Acquisition of Barr Extending Leadership and Accelerating Growth

  26. Slide 26: Barr Extends and Accelerates Our 2012 Strategy

    Barr Extends and Accelerates Our 2012 Strategy Increase Teva's market share in key markets Double our product portfolio Biotechnology: Next growth wave in generics Redefine customer service Innovative business Enhances our geographic footprint in Europe Enters top 5 in Germany Top 3 player in Poland

  27. Slide 27: Enhances Our Geographic Footprint

    Poland Creates top 3 pharmaceutical player Strengthens customer relationships Provides strong OTC portfolio + + Enhances Our Geographic Footprint Footprint Footprint Germany Enters into top 5 corporations Increases customer access: pharmacies, physicians, payers Creates broader portfolio - doubles o

  28. Slide 28: Strengthens Our Portfolio in Key Countries

    Strengthens Our Portfolio in Key Countries Number of products* 96 96 96 118 +74% Germany Germany 96 186 +94% Poland * Excluding overlapping products 3

  29. Slide 29: Creates Greater Customer Access

    Creates Greater Customer Access Broader portfolio, including important branded products More shelf share and attention from retailers Access to strong OTC portfolio Pharmacists Greater outreach through specialist sales forces Complementary portfolio for hospitals Physicians Broader portfolio offerin

  30. Slide 30: Key Takeaways

    Enhances global footprint Strengthens portfolio in key European countries Creates greater customer access and "Big-to-Big" value Key Takeaways + 5

  31. Slide 31: Teva's Acquisition of Barr: Eyal Desheh, CFO

    Eyal Desheh Chief Financial Officer Teva's Acquisition of Barr Extends Leadership and Accelerates Growth July 21, 2008

  32. Slide 32: Financial Considerations

    Financial Considerations Purchase consideration: $66.50 per one Barr share $39.90 in cash plus $26.60 in Teva shares for one Barr share Fixed share exchange rate of 0.6272 (representing $26.60) Purchase price based on Teva closing price on July 16 - $42.41 Total consideration $7.46 billion Plus appr

  33. Slide 33: Structural Considerations

    Structural Considerations Anticipated to be a tax free reorganization Structure maintains Teva's strong balance sheet Rating agencies affirmed our current rating Baa2 BBB+ Transaction is targeted to close in late 2008 2

  34. Slide 34: Highly Attractive Financial Outcome

    Highly Attractive Financial Outcome Projected 2008 combined revenues exceeds $13.7 billion Representing 15% growth over combined 2007 Anticipate strong cash flow from operations Over $3 billon in 2009 Over $5 billion in 2012 Accretive to GAAP earnings Within the fourth quarter following closing Cash

  35. Slide 35: Significant Synergy Opportunity

    Significant Synergy Opportunity At least $300 million in cost synergies by 2011 (fast ramp up) Synergies from manufacturing and API capabilities R&D synergies from pipeline reorganization Reduces recruiting requirement to achieve 2X goals SG&A synergies from infrastructure overlap Does not include s

  36. Slide 36: Maintaining Strong Balance Sheet and Credit Profile

    Maintaining Strong Balance Sheet and Credit Profile Strong liquidity position Maintain $1 billion post closing cash on hand Balance sheet flexibility provides liquidity for future strategic opportunities 3/31/08 3/31/08 Deal adjusted Debt & Minority Interest $5.4B $7.9B Equity $14.4B $16.5B Debt / 3

  37. Slide 37: Key Takeaways

    Key Takeaways GAAP EPS accretive in fourth quarter after closing New growth drivers Large synergy opportunities Improves cash flow Maintains strong balance sheet and credit profile + 6

Barr Pharmaceuticals — Merger or Acquisition (July 2008) on 6ix